Antiendothelial cell antibodies in thromboangiitis obliterans

American Journal of the Medical Sciences

Volumn 315, Issue 1, 1998, Pages 17-23

  Eichhorn, Jens ^a   Sima, Dagmar ^a   Lindschau, Garsten ^a   Turowski, Andreas ^a   Schmidt, Heiner ^a   Schneider, Wolfgang ^a   Haller, Hermann ^a   Luft, Friedrich C ^a,b,c  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b Department of Pathology

^c FRANZ VOLHARD CLINIC   (Germany)

Author keywords

Arteritis; Autoimmune disease; Endothelial cell antibodies; Endothelial cells; Thromboangiitis obliterans; Vasculitis

Indexed keywords

ANTINUCLEAR ANTIBODY; AUTOANTIBODY; AZATHIOPRINE; CARDIOLIPIN ANTIBODY; CELL ANTIBODY; ENDOTHELIUM ANTIBODY; NEUTROPHIL CYTOPLASMIC ANTIBODY; PREDNISOLONE; UNCLASSIFIED DRUG;

ADULT; ANTIBODY TITER; ARTICLE; BUERGER DISEASE; CIGARETTE SMOKING; CLINICAL ARTICLE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CYTOPLASM; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE MICROSCOPY; MALE;

EID: 0031975294     PISSN: 00029629     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000441-199801000-00004     Document Type: Article

References (40)

1. Buerger L. Thromboangiitis obliterans: A study of the vascular lesions leading to presenile spontaneous gangrene. Am J Med Sci. 1908; 136:567-80.
2. Cachovan M. Epidemiologie und geographische Verteilungsmuster der Thrombangiitis obliterans. In: Heidrich H; ed. Thrombangiitis obliterans: Morbus Winiwarter-Buerger. Stuttgart: Thieme; 1988:31-6.
3. Diehm C, Schäfer M. Das Buerger-Syndrom (Thrombangit-iis obliterans): Geschichte, Epidemiologie, Pathologie, Klinik, Diagnostik, und Therapie. Berlin: Springer; 1993.
4. Cutler DA, Runge MS. 86 Years of Buerger's disease: What have we learned? Am J Med Sci. 1995;309:74-5.
5. Bollinger A, Hollmann B, Schneider E, Fontana A. Thrombangitis obliterans: Diagnose und Therapie im Licht neuer immunologischer Befunde. Schweiz Med Wochenschr. 1979; 109: 537-43.
6. Mills JL, Tayloer JM Jr, Porter JM. Buerger's disease in modern era. Am J Surg. 1987; 154:123-9.
7. Hada M, Sakihama T, Kamiya K, Tasaka K, Ueno A. Cellular and humoral immune responses to vascular commponents in thromboangiitis obliterans. Angiology. 1993;44:533-40.
8. Humbel RL. Detection of antinuclear antibodies by immunofluorescence. In: van Venrooij WJ, Maini RN; eds. Manual of Biological Markers of Disease. Boston: Kluwer Academic . Publishers; 1993:1-16.
9. Hiepe F, Kiessig ST, Jahn S, Volk HD, Grunow R, Apostoloff E, v. Bachr R. A sensitive and class specific solid phase enzyme immunoassay for anti-DNA autoantibodies in supernatants of lymphocyte cultures and hybridomas. Biomed Biochim Acta. 1986;45:29-35.
10. Kurata N, Tan EM. Identification of antibodies to nuclear acidic antigens by counter immunoelectrophoresis. Arthritis Rheum. 1976; 19:574-9.
11. Kciscr HD, Weinstein J. Detection and identification of antibodies to saline extractable nuclear antigens by counter immunoelectrophoresis. Arthritis Rheum. 1980;23:1026-35.
12. Schössler W, Hiepe F, Couralt K, Forstmann B, Apostoloff E. Der Nachweis zirkulierender Immunkomplexe mittels eines clq-Festphasenenzymimmunoassays. Biomed Biochem Acta. 1983;42:1027.
13. Bleil L, Manger B, Winkler TH, Herman M, Burmester GR, Krapf FE, et al. The role of antineutrophil cytoplasm antibodies, anticardiolipin antibodies, von Willebrand factor antigen, and fibronectin for the diagnosis of systemic vasculitis. J Rheumatol. 1991; 18:1199-206.
14. Frampton G, Jayne DRW, GJ Perry, Lockwood CM, Cameron JS. Autoantibodies to endothelial cells and neutrophil cytoplasmic antigens in systemic vasculitis. Clin Exp Immunol. 1990; 82:227-32.
15. Göbel U, Eichhorn J, Kettritz R, Briedigkeit L, Sirna D, Lindschau C, et al. Disease activity and autoantibodies to endothelial cells in patients with Wegener's granulomatosis. Am J Kidney Dis. 1996;28:186-94.
16. Eichhorn J, Sima D, Thiele B, Lindschau C, Turowski A, Schmidt H, et al. Anti-endothelial cell antibodies in Takayasu arteritis. Circulation. 1996;94:2396-401.
17. Schössler W, Hicpe F, Couralt K, Porstmann B, Apostoloff E. Der Nachweis zirkulierender Immunkomplexe mittels eines clq-Festphasenenzymimmunoassays. Biomed Biochem Acta. 1983;42:1027-35.
18. von Winiwarter F. Ueber eine eigenthümliche Form von Endarteritis und Endophlebitis mit Gangrän des Fuβes. Arch Klin Chir. 1879;23:206-26.
19. Schoenberg DG, Schoenberg BS. Eponym: Leo Buerger-instrument, disease, and ego. South Med J. 1979; 72:737-8.
20. Wessler S, Ming S-C, Gurewich V, Freiman DG. A critical evaluation of thromboangiitis obliterans: The case against Buerger's disease. N Engl J Med. 1960;262:1149-60.
21. Papa M, Bass A, Adar R, Halperin Z, Schneidermann J, Becker CG, et al. Autoimmune mechanisms in thromboangiitis obliterans (Buerger's disease): The role of tobacco antigen and the major histocompatibility complex. Surgery. 1992; 111:527-31.
22. Corradi L, Zoppi A, Tettamanti F, Malamani GD, Lazzari P, Fogari E. Smoking habits and microalbuminuria in hypertensive patients with type 2 diabetes mellitus. J Hypertens. 1993;11:S190-1.
23. Pedrinelli R, Giampietro O, Carmassi F, Mellilo E, DellOma G, Catapano G, et al. Microalbuminuria and endothelial dysfunction in essential hypertension. Lancet. 1994;344:14-18.
24. Leu HJ. Zur Ätiologie der Thrombangiitis obliterans. In: Hei-drich H; eds. Thrombangiitis oblitérons: Morbus WiniwarterBuerger. Stuttgart: Thieme; 1988:17-8.
25. Spittcl JA. Thromboangiitis obliterans: An autoimmune disorder? N Engl J Med. 1983;308:1157-8.
26. Horsch AK, Horsch S, Mörtl H. Beitrag zur Diagnose der TAO durch den Nachweis von Anti-Elastin-Antikörpern. Vasa. 1985; 14:5-9.
27. Adar R, Papa MZ, Halpern Z, Mozes M, Shoshan S, Sofer B, et al. Cellular sensitivity to collagen in thromboangiitis obliterans. N Engl J Med. 1983;308:1113-6.
28. Ping Z, Pei-bin F, Wan-chao W, Wen-zu X, Xue-ming T, Ming Y, et al. Immunological studies on thromboangiitis obliterans. Chin Med J (Engl). 1989; 102:129-36.
29. Smolen JS, Youngchaiyud U, Weidinger P, Kojer M, Endler AT, Mayr WR, et al. Autoimmunological aspects of thromboangiitis obliterans (Buerger's disease). Clin Immunol Immunopathol. 1978; 11:168-77.
30. Gulati SM, Singh KS, Thusoo T, Saha K. Immunological studies in thromboangiitis obliterans (Buerger's disease). J Surg Res. 1979;27:287-93.
31. de Albuquerque RR, Delgado L, Correia P, Torrinha JF, Serrao D, Braga A. Circulating immune complexes in Buerger's disease. J Cardiovasc Surg. 1989;30:821-5.
32. Leung DYM, Geha RS, Newburger «JW, Burns JC, Fiers W, LaPierre LA, et al. Two monokines, interleukin 1 and tumor necrosis factor, enter cultured vascular endothelial cells susceptible to lysis by antibodies circulating during Kawasaki syndrome. J Exp Med. 1986; 164:1958-72.
33. Leung DYM, Moake JL, Havens PL, Kim M, Pober JS. Lytic anti-endothelial cell antibodies in haemolytic urémie syndrome. Lancet. 1988;2:183-6.
34. Van der Zee JM, Miltenburg AM, Siegert CE. Antiendothelial cell antibodies in systemic lupus erythematosus: Enhanced antibody binding to interleukin-1-stimulated endothelium. Int Arch Allergy Immunol. 1994; 104:131.
35. Brasilc L, Kremer JM, Clarke JL, Cerilli J. Identification of an autoantibody to vascular endothelial cell-specific antigens in patients with systemic vasculitis. Am J Med. 1989; 87:74-9.
36. 36: Frampton G, Chan D, Khouri N, Cameron JS. Pathogenetic aspects of autoantibodies to endothelial cells in systemic vasculitis. In: Gross WL; ed. ANCA-Associated Vasculitides: Immunological and Clinical Aspects. New York: Plenum; 1993:35-44.
37. Yap HK, Sakai RS, Bahn L, Rappaport V, Woo KT, Ananthuraman V, et al. Anti-vascular endothelial cell antibodies in patients with IgA nephropathy: Frequency and clinical significance. Clin Immunol Immunopathol. 1988;49:450-62.
38. Nusinow SR, Federici AB, Zimmerman TS. Increased von Willebrand factor antigen in the plasma of patients with vasculitis. Arthritis Rheum. 1984; 27:405-10.
39. Woolf AD, Wakerley G, Wallington TB, Scott DG, Dieppe PA. Factor VII related antigen in the assessment of vasculitis. Ann Rheum Dis. 1987;46:441-7.
40. Fiessinger JN, Schäfer M. Trial of iloprost versus aspirin treatment for critical limb ischaemia of thromboangiitis obliterans: The TAO study. Lancet. 1990; 335:555-7.